Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs IDEXX Laboratories, Inc. — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.78 (market cap $3.06B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13.2× State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF's market cap, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 16 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FLRN | IDXX | |
|---|---|---|
Market Cap | $3.06B | $40.43B |
Volume | 6,296,473 | 692,164 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $766.68 |
52-Week Low | $30.65 | $504.70 |
Typical Hold Time | 16 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.75 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with strong selling pressure in moving averages, while oscillators remain neutral. The ETF maintains consistent $0.11 quarterly dividend payments through 2026, providing income stability amid current market volatility.
FLRN offers protection against rising interest rates with near-zero duration exposure, though significant financial sector concentration presents risk. Current market sentiment reflects cautious optimism as institutional investors add positions while technical indicators suggest near-term pressure. The floating rate structure positions FLRN favorably in inflationary environments.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
